Physician profile
Byron May
NPI 1275252199
$7,747.12
in general payments reported to CMS, 2019-2025
28 companies · $2,582 in 2025
The $2,582 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $651 · 2023: $1,467 · 2024: $3,047 · 2025: $2,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,013 · Education: $83.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,013.15 |
| Education | $83.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,039.96 | 2022-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $722.43 | 2022-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $618.90 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $600.22 | 2022-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $577.73 | 2022-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $552.51 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.00 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $456.56 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $379.80 | 2023-2025 | |
| Amgen INC. | $305.13 | 2023-2025 | Tavneos, Parsabiv, Krystexxa |
| Novo Nordisk INC | $305.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Aurinia Pharma U.S., INC. | $213.32 | 2023-2024 | Lupkynis |
| Travere Therapeutics, INC. | $193.43 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $178.93 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $168.30 | 2023-2025 | Crysvita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $163.87 | 2022-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $158.37 | 2023 | Veltassa, Korsuva |
| Daiichi Sankyo INC. | $157.56 | 2023-2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $152.52 | 2024 | Soliris, Ultomiris |
| Abbvie INC. | $116.31 | 2022 | |
| Genzyme Corporation | $72.20 | 2023-2024 | |
| Glaxosmithkline, LLC. | $28.87 | 2023-2024 | Benlysta, Jesduvroq |
| Takeda Pharmaceuticals U.S.A., INC. | $24.81 | 2022 | |
| Astellas Pharma US INC | $24.60 | 2024 | Cresemba |
| Opko Pharmaceuticals, LLC | $22.45 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $20.07 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.09 | 2023 | Givlaari |
| Daxor Corporation | $10.16 | 2023 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.